Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFVT-2101
- Development stage
- Preclinical
- Lead developer
- Affivant Sciences
- Modality
- Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AFVT-2101 is a third-generation innate cell engager (ICE) being developed by Affivant Sciences for the treatment of solid tumors, including ovarian, lung, kidney, and breast cancers. It is designed to target CD16 (FcγRIIIa) on innate immune cells, such as natural killer (NK) cells and macrophages, and redirect them toward an antigen that is highly overexpressed on various epithelial tumors. By leveraging high-affinity, specific binding to CD16, AFVT-2101 aims to enhance antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. The program is currently in the IND-enabling stage of development, with studies spanning from discovery through preclinical evaluation.
02
Targets
FOLR1 (FRα)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on AFVT-2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFVT-2101.